Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Uterine Cervical Neoplasms 3Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Breast Neoplasms 2Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Prostate Adenocarcinoma 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Male Urogenital Diseases 1Lymphedema 1Lung Neoplasms 1Gallbladder Neoplasms 1Financial Stress 1Female Urogenital Diseases 1Endometrial Neoplasms 1Encopresis 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Gemcitabine 29pembrolizumab 20Cisplatin 20Magnetic Resonance Spectroscopy 17Specimen Handling 16Mitomycin 10enfortumab vedotin 9durvalumab 9Cystoscopy 9avelumab 8Nivolumab 8Fluorouracil 8Carboplatin 8Radiation 7Cystectomy 6atezolizumab 5Transurethral Resection of Bladder 5Radiotherapy 5Mitozytrex 5Docetaxel 5Biopsy 5tremelimumab 4sacituzumab govitecan 4erdafitinib 4dehydroftorafur 4Platinum 4Immunoglobulin G 4Disulfides 41,2-diaminocyclohexaneplatinum II citrate 4disitamab vedotin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Radiation Dose Hypofractionation × 90 days × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NRG Oncology

Phase 3 Recruiting
486 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡